Better understanding and new challenges in high grade lymphomas

Diffuse large B-cell lymphoma (DLBCL), comprise the most commonly diagnosed non-Hodgkin lymphoma. Approximately 60–65% of patients can be cured with standard front-line therapy R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone). However, the progress in the understanding of the disease has led us to appreciate its underlying heterogeneity.